Cargando…

SGLT2 inhibitors and renal complications in type 1 diabetes

Detalles Bibliográficos
Autor principal:	Petrie, John R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492012/ https://www.ncbi.nlm.nih.gov/pubmed/32946814 http://dx.doi.org/10.1016/S2213-8587(20)30311-9

Ejemplares similares

Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy
por: Young, Katherine G., et al.
Publicado: (2023)

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?
por: Verma, Subodh
Publicado: (2020)

SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes
por: Hodrea, Judit, et al.
Publicado: (2022)

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015)

SGLT inhibitor adjunct therapy in type 1 diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2018)

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
por: Evans, Marc, et al.
Publicado: (2019)

Hereditary renal glycosuria, diabetes and responses to SGLT2 inhibitor
por: Ren, Qian, et al.
Publicado: (2022)

Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
por: El Hage, Lea, et al.
Publicado: (2020)

SGLT2 inhibitors: An answer to diabetes or a question to its complications?
por: Priya, et al.
Publicado: (2022)

SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
por: Saisho, Yoshifumi
Publicado: (2020)

The “discordant doppelganger dilemma”: SGLT2i mimics therapeutic carbohydrate restriction - food choice first over pharma?
por: Murray, Scott W., et al.
Publicado: (2021)

Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure
por: Packer, Milton
Publicado: (2023)

Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?
por: Mantsounga, Chris Sorel, et al.
Publicado: (2019)

Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
por: Giorgino, Francesco, et al.
Publicado: (2020)

Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors
por: Scholtes, Rosalie A., et al.
Publicado: (2021)

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
por: Steven, Sebastian, et al.
Publicado: (2017)

Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin
por: KATSUDA, Yoshiaki, et al.
Publicado: (2015)

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
por: Nauck, Michael A
Publicado: (2014)

Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
por: Gomez-Peralta, Fernando, et al.
Publicado: (2017)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus
por: Peppa, Melpomeni, et al.
Publicado: (2023)

SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects
por: Janssens, Birgit, et al.
Publicado: (2020)

SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules
por: Wang, Yajiao, et al.
Publicado: (2023)

Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient
por: Bell, David S. H.
Publicado: (2015)

Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021
por: Malik, Mariam Elmegaard, et al.
Publicado: (2023)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
por: Wheeler, David C., et al.
Publicado: (2020)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

Erratum to: Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
por: Gomez-Peralta, Fernando, et al.
Publicado: (2017)

Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?
por: Bernardi, Marco, et al.
Publicado: (2023)

Neratinib is an MST1 inhibitor and restores pancreatic β-cells in diabetes
por: Ardestani, Amin, et al.
Publicado: (2019)

Type 2 diabetes prevention goes digital
por: Samarasinghe, Suhaniya N.S., et al.
Publicado: (2022)

Chronic limb threatening disease, diabetic nephropathy and diabetic retinopathy in patients with type 1 diabetes
por: Jonas, Jost B.
Publicado: (2023)

Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
por: Alkabbani, Wajd, et al.
Publicado: (2021)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
por: Dąbrowski, Mariusz
Publicado: (2021)

Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
por: Ghezzi, Chiara, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_54b7m9p4cbnkobt9b2a5euh9bs